Gta: glyceryltriacetate (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 307 | Canavan disease | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00278707 (ClinicalTrials.gov) | January 2006 | 15/1/2006 | GTA-Glyceryltriacetate for Canavan Disease | Phase 1 Treatment With GTA in Two Infant With Canavan Disease | Infantile Canavan Disease;Deficiency Disease, Aspartoacylase | Drug: GTA: Glyceryltriacetate | Sheba Medical Center | NULL | Active, not recruiting | N/A | 15 Months | Both | 5 | Phase 1 | Israel |